ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,318.09
0.19%
Dow Jones
40,000.79
0.23%
US Dollar vs MXN
16.6868
0.02%
Brent Oil
82.915
0.31%
Bitcoin
65,287.03
-1.47%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) Noticias

ARGX argenx SE

374.74
-2.22 (-0.59%)
Última actualización: 11:59:07
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
argenx SE ARGX NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-2.22 -0.59% 374.74 11:59:07
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
375.90 373.62 378.05 376.96
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
09/5/202406:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/5/202400:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
08/5/202405:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/5/202416:30GLOBEargenx announces results of Annual General Meeting of..
07/5/202400:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
02/5/202400:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
16/4/202400:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/3/202401:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26/3/202415:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/3/202401:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
08/3/202405:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/3/202415:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29/2/202415:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/2/202400:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/2/202400:00GLOBEargenx to Present at Upcoming Investor Conferences
22/2/202400:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/2/202405:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/2/202400:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18/1/202405:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/1/202400:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08/1/202405:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202400:00GLOBEargenx Highlights 2024 Strategic Priorities
02/1/202400:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
20/12/202311:37DJNArgenx Down Nearly 26%, on Pace for Record Percent Decrease..
20/12/202305:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202300:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
28/11/202310:16DJNArgenx Down Over 10%, On Track for Largest Percent Decrease..
28/11/202306:03DJNArgenx Shares Down After Vyvgart Study Misses Primary..
28/11/202305:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202300:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
17/11/202305:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/11/202306:40GLOBEargenx Announces European Commission Approval of..
01/11/202315:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202301:00GLOBEargenx to Present at Upcoming Investor Conferences
31/10/202308:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202301:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202300:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
27/9/202315:42EDGAR2Form S-8 - Securities to be offered to employees in employee..
21/9/202307:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/9/202300:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15/9/202300:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30/8/202300:00GLOBEargenx to Present at Upcoming Investor Conferences
27/7/202305:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/7/202300:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
24/7/202315:30GLOBEargenx announces closing of global offering
20/7/202315:51EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/7/202300:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
19/7/202316:58GLOBEargenx announces full exercise of underwriters’ option to..
18/7/202320:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
17/7/202315:58DJNArgenx Launches $750 Million Global Offering

Su Consulta Reciente

NASDAQ
ARGX
argenx
AQSE
ARBB
Arbuthnot Banking
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados